Clinical trials are an important way to improve treatment for people with cancer. While most are continuing during the COVID-19 pandemic, the period of time that clinical trials are available and recruiting may change quickly. If you would like to get involved in a clinical trial, speak to your treatment team or the health service where the clinical trial is being undertaken, to confirm it is open and appropriate for you. For cancer information and support, call Cancer Council's experienced cancer nurses on 13 11 20 Monday to Friday from 9am-5pm.

NCT04630756 : A Modular Phase I/II, Open-label, Multicentre Study to Assess AZD4573 in Novel Combinations With Anti-cancer Agents in Patients With Advanced Haematological Malignancies

Male or<br/>FemaleGender Male or

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

One/TwoPhase One/Two

18-130Age 18-130

Blood<br/>CancersCancer LocationBlood

Systemic therapy | Blood / Myeloma / LymphomaB-Cell Non Hodgkin Lymphoma,Diffuse Large Cell Lymphoma,Lymphoma,Mantle Cell Lymphoma

Trial Overview Read MoreRead more

This phase I/II study is trying to determine the appropriate dosing of a targeted therapy (AZD4573) alone, and then evaluate how effective it is when combined with another targeted therapy (acalabrutinib), in people with advanced blood cancers.

This trial is treating patients with advanced blood cancers, including Diffuse large B-cell lymphoma, Marginal zone lymphoma, Germinal Centre B-cell lymphoma, non-GCB Diffuse large B-cell lymphoma and Mantle Cell Lymphoma .

This is a systemic therapy trial.

You may be able to join this trial if:

  • You are able to swallow medication by mouth.
  • You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
  • You have had treatment, but your cancer has come back.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Modular Phase I/II, Open-label, Multicentre Study to Assess AZD4573 in Novel Combinations With Anti-cancer Agents in Patients With Advanced Haematological Malignancies

Commercial Sponsor



This is a non-randomised trial that has two modules, each with two parts. In Module 1 Part A, participants will receive ascending doses of AZD4573 (administered intravenously [via IV]) once weekly, in combination with oral, twice daily doses of acalabrutinib. Part A will have three different cohorts, each with different target dose levels of AZD4573. The primary objective of Part A is to determine the maximum tolerated dose for Part B. In Module 1 Part B, participants will receive AZD4573 at the dose level determined in Part A. Module 2 Part A has two phases. In Phase 1, participants will receive AZD4573 alone (administered via IV once weekly). In Phase 2, participants will receive AZD4573 (administered via IV once weekly) in combination with acalabrutinib (orally, twice daily). Module 2 Part B will be determined based on the data that emerges from Part A.

Recruiting Hospitals Read MoreRead more

Monash Health Haematology Research Unit
Miss Jeanette Gamgee
03 9594 4044

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.